MedTrace Logo

Rapid Structural and Functional Improvements in Following 0.19 mg Fluocinolone Acetonide (FAc) Implant in Diabetic Macular Edema Patients With Poor Visual Acuity: 12-month Audit Results From United Arab Emirates

NCT03590587 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2018-07-18

No results posted yet for this study

Summary

The Health Authority - Abu Dhabi (HAAD) approved the reimbursement of the slow release FAc implant (ILUVIEN) and it is now available for the treatment of diabetic macular edema (DME) in persons who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. We performed a retrospective 12-month audit to assess the efficacy and safety of the FAc implant in our clinical practice.

Conditions

Interventions

DRUG

0.19 mg fluocinolone acetonide (FAc) implant

0.19 mg fluocinolone acetonide (FAc) implant

DEVICE

0.19 mg fluocinolone acetonide (FAc) implant

0.19 mg fluocinolone acetonide (FAc) implant

Sponsors & Collaborators

  • Sheikh Khalifa Medical City

    collaborator OTHER

  • Benha University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-13
Primary Completion
2018-09-15
Completion
2018-09-16
FDA Drug
Yes
FDA Device
Yes

Countries

  • United Arab Emirates

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03590587 on ClinicalTrials.gov